Minirin for the sublingual application to manage diabetes insipidus in the patients treated for brain tumours

Mazerkina N.A.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko", Moskva

Authors:

Mazerkina N.A.

More about the authors

Journal: Problems of Endocrinology. 2012;58(5): 46‑49

Downloaded: 8

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Mazerkina NA. Minirin for the sublingual application to manage diabetes insipidus in the patients treated for brain tumours. Problems of Endocrinology. 2012;58(5):46‑49. (In Russ.)

Close metadata

Recommended articles:

Analysis of a series of 14 clinical cases of neurosurgical treatment of hypophysitis. Burdenko's Journal of Neurosurgery. 2025;(2):39-47

The objective of the present study was to compare the effectiveness of desmopressin (standard oral and sublingual minirin tablets) and patient compliance with these two therapeutic modalities. The study included 51 patients at the age from 1 to 23 years presenting with diabetes insipidus (DI) at least 6 months in duration who had undergone the surgical treatment of craniopharyngioma (n=25), germinoma (n=21, glioma (n=3), and pituitary adenoma (n=2). The patients were transferred from the oral minirin formulation to the sublingual one (the dose of 100 mcg of oral minirin is equivalent to a 60 mcg sublingual tablet). The patients were interviewed to estimate their preference as regards either therapeutic modality within one week after the onset of the treatment. It turned out after the completion of the study that 30 of the 51 patients (59%) adhered to the new sublingual formulation of minirin. Their preferences were unrelated to the age of the patients, diagnosis, and duration of the disease but significantly correlated with a single dose of the preparation. Specifically, the single dose was lower than 1 tablet in 71% of the patients who chose to use oral minirin. No adverse reactions in response to the treatment with sublingual minirin were documented.

Keywords:

diabetes insipidus

desmopressin

minirin

Authors:

Mazerkina N.A.

FGBU "NII neĭrokhirurgii im. akad. N.N. Burdenko", Moskva

List of references:

Melmed S. The pituitary. 2nd ed. Blackwell Science Inc 2002; 7.
Nesakharnyi diabet. V: Detskaya endokrinologiya. Rukovodstvo dlya vrachei. Pod red. I.I. Dedova, V.A. Peterkovoi. M: Universum Pablishing 2006; 600.
Bode H.H. Disorders of posterior pituitary. In: Clinical pediatric endocrinology. Ed. S.A. Kaplan. Philadelphia: WB Saunders; 63-68.
Pivonello R., De Bellis A., Faggiano A., Di Salle F., Petretta M., Di Somma C., Perrino S., Altucci P., Bizzarro A., Bellastella A., Lombardi G., Colao A. Central Diabetes Insipidus and Autoimmunity: Relationship between the Occurrence of Antibodies to Arginine Vasopressin-Secreting Cells and Clinical, Immunological, and Radiological Features in a Large Cohort of Patients with Central Diabetes Insipidus of Known and Unknown Etiology. J Clin Endocrinol Metab 2004; 88: 4: 1629-1636.
Mazerkina N.A. Endokrinnye narusheniya posle kompleksnoi terapii zlokachestvennykh opukholei zadnei cherepnoi yamki i khiazmal'no-sellyarnoi oblasti u detei: Avtoref. dis. ... d-ra med. nauk. M 2008.
Mazerkina N.A., Konovalov A.N., Gorelyshev S.K., Semenova Zh.B., Krasnova T.S., Tenedieva V.D. Endokrinnye narusheniya pri kraniofaringiomakh u detei: zavisimost' ot lokalizatsii opukholi. Zhurn vopr neirokhir 2008; 1: 23-29.
Savin I.A. Vodno-elektrolitnye narusheniya v neirokhirurgii. V kn.: Intensivnaya terapiya. Natsional'noe rukovodstvo. V 2 t. M: Geotar-Media 2009; 1: 952-960.
Agha A., Rogers B., Mylotte D., Taleb F., Tormey W., Phillips J., Thompson C.J. Neuroendocrine dysfunction in he acute phase of traumatic brain injury. Clin Endocrinol (Oxford) 2004; 60: 584-591.
Yuan X.Q., Wade C.E. Neuroendocrine abnormalities in patients with traumatic brain injury. Front Neuroendocrinol 1991; 12: 209-230.
Dzeranova L.K., Pigarova E.A. Lechenie nesakharnogo diabeta. Rus med zhurn 2005; 13: 28.
SmPC (Accessed 12 May 2011) DDVP Melt 60 mcg, 120 mcg nd 240 mcg oral lyophilisate 13/11/2009 Electronic Medicines Compendium http:/www.medicines.org.uk/EMC/medicine/DDAVP+Melt+60mcg%2c+120mcg+and+240mcg+g++oral+ lyophilisate
Juul K.V., Bichet D.G., Nørgaard J.P. Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. Endocrine 2011; 1: 67-74.
Rahman M., Friedman W.A. Hyponatremia in neurosurgical patients: clinical guidelines development. Neurosurgery 2009; 65: 5: 925-935; discussion 935-936.
Standing J.F., Tuleu C. Pediatric formulation - getting to the heart of the problem. Int J Pharm 2005; 300: 56-66.
Robson W.L., Leung A.K., Norgaard J.P. The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol 2007; 178: 1: 24-30.
Osterberg R.M., Savic M.O., Karlsson U.S., Simonsson U.S., Nørgaard J.P., Walle J.V., Agersø H. Pharmacocinetics of desmopressin as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol 2006; 46: 1204-1211.

Close metadata